Previous 10 | Next 10 |
Marker Therapeutics ( MRKR ) is gearing up for a big catalyst in Q3 of 2019. This is going to be data from its phase 1/2 study using its MultiTAA cell therapy product to treat patients with pancreatic solid tumors. The MultiTAA product from the biotech offers many advantages over current CAR...
Marker Therapeutics (NASDAQ: MRKR ) is 3.5% lower postmarket after the filing of a $200M mixed shelf registration . More news on: Marker Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
HOUSTON , May 21, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...
Marker Therapeutics (NASDAQ: MRKR ): Q1 GAAP EPS of -$0.12 beats by $0.03 . More news on: Marker Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
HOUSTON , May 9, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, ...
HOUSTON , May 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...
Yangtze River Port and Logistics (NASDAQ: YRIV ) -35% . More news on: Yangtze River Port and Logistics Limited, Marker Therapeutics, Inc., Stocks on the move, Read more ...
Seelos Therapeutics (NASDAQ: SEEL ) +32% on FY results and pipeline developments . More news on: Seelos Therapeutics, Inc., Urban Tea, Inc., Progress Software Corporation, Stocks on the move, Read more ...
Marker Therapeutics (NASDAQ: MRKR ) provides a business and clinical update, as well as an overview of upcoming milestones for 2019. More news on: Marker Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
HOUSTON , March 28, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indicat...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...